Although SB225002 was first developed for the treatment of inflammatory diseases [20], [21], recent studies suggest that retrovirus infections, Wilms’ tumor and Alzheimer’s disease may be potential therapeutic indications for CXCR2 antagonist [22], [23], [24]. This evidence concerns the gene CXCR2 and Wilms tumor.